COST-EFFECTIVENESS OF BENDAMUSTINE VERSUS IBRITUMOMAB TIUXETAN IN THE TREATMENT OF RITUXIMAB-REFRACTORY INDOLENT NON-HODGKIN'S LYMPHOMA IN CANADA

被引：0
|
作者：
Lachaine, J. [1 ]
Beauchemin, C. [1 ]
Mathurin, K. [1 ]
Aissa, F. [2 ]
机构：
[1] Univ Montreal, Montreal, PQ, Canada
[2] Lundbeck Canada Inc, Montreal, PQ, Canada
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A141 / A142
页数：2
相关论文
共 50 条
  • [21] Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-cell Non-Hodgkin Lymphoma Results From a Multicenter Study
    Kahl, Brad S.
    Bartlett, Nancy L.
    Leonard, John P.
    Chen, Ling
    Ganjoo, Kristen
    Williams, Michael E.
    Czuczman, Myron S.
    Robinson, K. Sue
    Joyce, Robin
    van der Jagt, Richard H.
    Cheson, Bruce D.
    CANCER, 2010, 116 (01) : 106 - 114
  • [22] A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma
    Khan, Khuda D.
    Emmanouilides, Christos
    Benson, Don M., Jr.
    Hurst, Deborah
    Garcia, Pablo
    Michelson, Glenn
    Milan, Sandra
    Ferketich, Amy K.
    Piro, Lawrence
    Leonard, John P.
    Porcu, Pierluigi
    Eisenbeis, Charles F.
    Banks, Amy L.
    Chen, Lei
    Byrd, John C.
    Caligiuri, Michael A.
    CLINICAL CANCER RESEARCH, 2006, 12 (23) : 7046 - 7053
  • [23] Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study
    Friedberg, Jonathan W.
    Cohen, Philip
    Chen, Ling
    Robinson, K. Sue
    Forero-Torres, Andres
    La Casce, Ann S.
    Fayad, Luis E.
    Bessudo, Alberto
    Camacho, Elber S.
    Williams, Michael E.
    Van der Jagt, Richard H.
    Oliver, Jennifer W.
    Cheson, Bruce D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) : 204 - 210
  • [24] GADOLIN: PRIMARY RESULTS FROM A PHASE III STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE COMPARED WITH BENDAMUSTINE ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
    Sehn, L.
    Chua, N.
    Mayer, J.
    Dueck, G.
    Trneny, M.
    Bouabdallah, K.
    Fowler, N.
    Delwail, V.
    Press, O.
    Salles, G.
    Gribben, J.
    Lennard, A.
    Lugtenburg, P.
    Franklin, N.
    Wassner-Fritsch, E.
    Fingerle-Rowson, G.
    Cheson, B.
    HAEMATOLOGICA, 2015, 100 : 273 - 273
  • [25] GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma
    Sehn, Laurie Helen
    Chua, Neil Sun
    Mayer, Jiri
    Dueck, Gregory Scott
    Trneny, Marek
    Bouabdallah, Kamal
    Fowler, Nathan Hale
    Delwail, Vincent
    Press, Oliver W.
    Salles, Gilles A.
    Gribben, John G.
    Lennard, Anne
    Lugtenburg, Pieternella J.
    Franklin, Natalie
    Fritsch, Elisabeth Wassner
    Fingerle-Rowson, Guenter
    Cheson, Bruce D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)
  • [26] Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
    Sehn, Laurie H.
    Chua, Neil
    Mayer, Jiri
    Dueck, Gregg
    Trneny, Marek
    Bouabdallah, Kamal
    Fowler, Nathan
    Delwail, Vincent
    Press, Oliver
    Salles, Gilles
    Gribben, John
    Lennard, Anne
    Lugtenburg, Pieternella J.
    Dimier, Natalie
    Wassner-Fritsch, Elisabeth
    Fingerle-Rowson, Guenter
    Cheson, Bruce D.
    LANCET ONCOLOGY, 2016, 17 (08): : 1081 - 1093
  • [27] Cost effectiveness of rituximab plus CVP in previously untreated indolent non-Hodgkin's lymphoma
    Maturi, B.
    Tong, W.
    Gyldmark, M.
    Creeden, J.
    Aultman, R.
    Jost, F. F.
    VALUE IN HEALTH, 2006, 9 (06) : A288 - A288
  • [28] Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma
    Moosmann, Peter
    Heizmann, Marc
    Kotrubczik, Nina
    Wernli, Martin
    Bargetzi, Mario
    LEUKEMIA & LYMPHOMA, 2010, 51 (01) : 149 - 152
  • [29] 90Yttrium-ibritumomab tiuxetan:: a novel treatment for non-Hodgkin's lymphoma
    Blum, KA
    Bartlett, NL
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (08) : 1323 - 1331
  • [30] The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
    Friedberg, Jonathan W.
    Vose, Julie M.
    Kelly, Jennifer L.
    Young, Faith
    Bernstein, Steven H.
    Peterson, Derick
    Rich, Lynn
    Blumel, Susan
    Proia, Nicole K.
    Liesveld, Jane
    Fisher, Richard I.
    Armitage, James O.
    Grant, Steven
    Leonard, John P.
    BLOOD, 2011, 117 (10) : 2807 - 2812
12345